With this in mind, they tested Y-27632, a selective inhibitor of a recently identified kinase, p160-Rho-associated coiled-coil kinase (ROCK). Upon treatment with this compound, dissociation ...

Redx Pharma plc has divulged Rho kinase 1 (ROCK1) and 2 (ROCK2) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, fibrosis, inflammatory and neurological disorders.